The Lancet Commission on Prostate Cancer – Nicholas James & James N’Dow
April 10, 2024
Nicholas James and James N’Dow delve into the findings and objectives of the Lancet Prostate Cancer Commission. Professor James outlines the initiative’s global scope and multidisciplinary approach to tackling prostate cancer, emphasizing the diverse representation and expertise spanning various regions and specialties. The discussion highlights the comprehensive analysis undertaken over three years, culminating in a document that offers innovative recommendations for future strategies. Professor N’Dow, leading the diagnostic and screening section, addresses the complexities of early diagnosis and the potential for risk-adapted detection to balance the scales between overdiagnosis in high-income regions and late-stage presentations in lower-income countries. Both experts stress the imminent surge in prostate cancer cases, particularly in sub-Saharan Africa, underscoring the need for scalable diagnostic systems, education, and a proactive approach to healthcare disparities.
Biographies:
Professor Nicholas James, MBBS, FRCP, FRCR, Ph.D., Professor of Clinical Oncology at the Institute of Cancer Research at Royal Marsden Hospital, London
James N’Dow, Professor, Chair in Surgery (Clin), Director of the Academic Urology Unit, University of Aberdeen
Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, MA
Related Content:
The Lancet Commission on prostate cancer: planning for the surge in cases
Read the Full Video Transcript
Alicia Morgans: Hi, I’m so excited to be here to speak with two authors on the Lancet Prostate Cancer Commission work that is out now in the Lancet. So excited to speak with both of you.
Nicholas James: Hi, nice to be here as always.
James N’Dow: Yeah.
Alicia Morgans: Wonderful.
James N’Dow: Pleasure.
Alicia Morgans: Thank you both. Can you just introduce yourselves, please? And we’ll start with Professor N’Dow, please.
James N’Dow: I’m James N’Dow, Professor of Urological Surgery in Aberdeen in Scotland. And I’m Adjunct Secretary General and the EU executive looking after the education portfolio. And I was honored to work alongside Nick James who chaired this whole endeavor.
Alicia Morgans: Wonderful. And the chair himself, Dr. James, Professor James.
Nicholas James: Yeah. Nick James, I’m Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research in London and the Royal Marsden Hospital. And in this context, I chaired the commission over the last three years.
Alicia Morgans: Wonderful. Nick, we’ll start with you. Can you tell me a little bit about why the Lancet put together this gro
